Abstract
Background and aims This study was performed to analyse the influence of coffee consumption on clinical outcomes in colombian patients with systemic lupus erythematosus (SLE).
Methods A cross-sectional analytical study was conducted in 731 Colombian patients with SLE in whom coffee consumption and its frequency was assessed. Differences in clinical outcomes (i.e., cardiovascular disease, age-at-onset, organ damage, polyautoimmunity, acute activity determined by SLEDAI, and clinical remission) were determined between drinkers and non-drinkers, as well as by frequency of consumption. Association was examined by chi-square and multivariate regression analyses.
Results Sociodemographic and clinical characteristics of the patients are shown in table 1. Out of a total of 731 patients, 70% were current coffee drinkers, 57% reported daily consumption, 10% weekly consumption and 3% monthly consumption. Coffee intake was found to be associated with SLE age at onset, cardiovascular disease and 6 months clinical remission (Table 2). According to the frequency of intake, daily consumption was associated to reduced risk of early age-at-onset and a positive association with 6 months clinical remission (OR: 0,45 95% CI 0,25–0,81 and OR: 1,55 95% CI 1,07–2,25, respectively). No differences were found for organ damage, polyautoimmunity and acute SLE activity.
Sociodemographic and clinical characteristics of the SLE patients
Association between coffee consumption and clinical outcomes in SLE patients (N=731)
Conclusions In Colombian SLE patients with coffee consumption, a reduced risk of early age-at-onset and cardiovascular disease was recognised. Also, a positive association with 6 month clinical remission was found. Due to the methodology of the study and its limitations, it is not possible to conclude a causal relationship. More studies must be done to clarify the influence of coffee in autoinmune disease.
